Iovance BiotherapeuticsIOVA
IOVA
About: Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.
Employees: 838
0
Funds holding %
of 7,323 funds
0
Analysts bullish %
of 6 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
20% more call options, than puts
Call options by funds: $7.88M | Put options by funds: $6.57M
9% more first-time investments, than exits
New positions opened: 58 | Existing positions closed: 53
9% more repeat investments, than reductions
Existing positions increased: 99 | Existing positions reduced: 91
0% more funds holding
Funds holding: 299 [Q4 2024] → 300 (+1) [Q1 2025]
6.21% less ownership
Funds ownership: 79.24% [Q4 2024] → 73.03% (-6.21%) [Q1 2025]
55% less capital invested
Capital invested by funds: $1.79B [Q4 2024] → $798M (-$989M) [Q1 2025]
71% less funds holding in top 10
Funds holding in top 10: 7 [Q4 2024] → 2 (-5) [Q1 2025]
Research analyst outlook
6 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$2
25%
downside
Avg. target
$11.50
331%
upside
High target
$25
836%
upside
6 analyst ratings
5 positive
83%
1 neutral
17%
0 negative
0%
Chardan Capital Geulah Livshits | 836%upside $25 | Buy Maintained | 23 Jul 2025 |
UBS David Dai | 25%downside $2 | Neutral Downgraded | 16 May 2025 |
Goldman Sachs Andrea Tan | 200%upside $8 | Buy Maintained | 12 May 2025 |
Mizuho Mara Goldstein | 275%upside $10 | Outperform Maintained | 12 May 2025 |
Barclays Peter Lawson | 50%upside $4 | Overweight Maintained | 12 May 2025 |
Financial journalist opinion
Based on 73 articles about IOVA published over the past 30 days
Positive
The Motley Fool
11 hours ago
Is Iovance Biotherapeutics Stock Due for a Big Rally?
Shares of Iovance Biotherapeutics (IOVA -1.02%) have been in a free fall this past year, but in recent weeks, they have experienced a bit of a surge in value. The volatile biotech stock has been picking up steam, and the share price is up roughly 67% in just the past month.
Positive
The Motley Fool
1 day ago
This Beaten-Down Healthcare Stock Could Jump 720%, According to a Wall Street Analyst. Is It Time to Buy?
Shares of Iovance Biotherapeutics (IOVA -5.91%) are down about 75% from a high-water mark they set last December. Up and down Wall Street, investment bank analysts tasked with following the commercial-stage cancer drug developer are arguing about whether it's fallen too far or not far enough.
Neutral
Invezz
1 week ago
Here's why Iova stock surged 32% today and why the rally might not be over
Iova stock rallied 32% on Wednesday, snapping out of a long, sluggish stretch that had frustrated investors for months. The Iovance Biotherapeutics (NASDAQ: IOVA) shares have been stuck in a tight range after a rough year, but today's move was sharp enough to turn heads.
Positive
The Motley Fool
1 week ago
This Healthcare Stock Just Hit a 52-Week Low -- but Wall Street Sees 380% Upside
Investing in penny stocks -- companies with share prices under around $5 apiece -- could lead to monster returns over the long run. The flip side is that these corporations tend to carry above-average risk.
Neutral
GlobeNewsWire
1 week ago
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
SAN CARLOS, Calif., July 18, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on July 17, 2025 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 138,190 shares of Iovance's common stock to 20 new, non-executive employees.
Neutral
Seeking Alpha
1 week ago
Iovance: I'm Switching From Sell To Buy Despite Likely Approval For Rival Drug
Iovance Biotherapeutics, Inc. stock is down nearly 30% since my "sell" recommendation in April. Q1 earnings disappointed, with Amtagvi sales underperforming the Street's expectations and guidance revised downward. The impending approval of a rival therapy in the advanced melanoma space - Replimmune's RP1 - is another cause for concern.
Neutral
GlobeNewsWire
2 weeks ago
IOVANCE INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Iovance Biotherapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Iovance (IOVA) To Contact Him Directly To Discuss Their Options
Neutral
GlobeNewsWire
2 weeks ago
Iovance Biotherapeutics Appoints Corleen Roche as Chief Financial Officer
SAN CARLOS, Calif., July 15, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced the appointment of Corleen Roche as Chief Financial Officer (CFO), effective August 6th, 2025.
Neutral
GlobeNewsWire
2 weeks ago
Levi & Korsinsky Reminds Iovance Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 14, 2025 – IOVA
NEW YORK, July 14, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Iovance Biotherapeutics, Inc. ("Iovance" or the "Company") (NASDAQ: IOVA) of a class action securities lawsuit.
Neutral
Business Wire
2 weeks ago
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Iovance Biotherapeutics
NEW YORK--(BUSINESS WIRE)---- $IOVA #ClassAction--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Iovance Biotherapeutics, Inc. (“Iovance” or the “Company”) (NASDAQ: IOVA) and reminds investors of the July 14, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia.
Charts implemented using Lightweight Charts™